CLAIMS:

1. An effective amount of at least one complex of nocardamine (desferrioxamine E) with a metal, any combination/s of said complexes, any pharmaceutical composition/s of the complexes comprising any carrier/s, matrix or vehicle/s for use in a method for modulating cytokine levels in a cell, wherein said metal is selected from the group consisting of zinc, gallium or any ionic forms thereof.

2. The complex for use according to claim 1, wherein said metal ion is Zn^{2+}.

3. The complex for use according to claim 2, wherein said complex is a complex of nocardamine with Zn^{2+}.

4. The complex for use according to claim 1, wherein said complex is a complex of nocardamine with Ga^{3+}.

5. The complex for use according to claim 1, wherein said modulation is at least one of reduction or elevation of cytokine levels in said cell.

6. The complex for use according to claim 5, wherein said cytokine is at least one of, at least one pro-inflammatory cytokine and at least one anti-inflammatory cytokine.

7. The complex for use according to claim 5, wherein said method reduces the level of at least one pro-inflammatory cytokine in said cell, and wherein said pro-inflammatory cytokine is at least one of: IL-1α, IL-6, TNF- α and IL-17.

8. The complex for use according to claim 6, wherein said method elevates the level of at least one anti-inflammatory cytokine in said cell and wherein said anti-inflammatory cytokine is at least one of: IL-13, IL-4 and IL-10.

9. The complex for use according to any one of claims 1 to 4, for modulating cytokine levels in a subject, said method comprising the step of administering to said subject an effective amount of at least one complex of nocardamine with a metal, any combination/s of said complexes, any pharmaceutical composition/s of the complexes
comprising any carrier/s, matrix or vehicle/s.

10. The complex for use according to claim 9, wherein said modulation is reduction of the level of at least one pro-inflammatory cytokine in said subject, said pro-inflammatory cytokine is at least one of IL-1α, IL-6, TNF- α and IL-17.

11. The complex for use according to claim 9, wherein modulation is elevation of the level of at least one anti-inflammatory cytokine in said subject, said anti-inflammatory cytokine is at least one of IL-13, IL-4 and IL-10.

12. The complex for use according to claim 9, wherein said subject is suffering from a disorder associated with at least one of elevated level/s of at least one pro-inflammatory cytokine and reduced level/s of at least one anti-inflammatory cytokine.

13. The complex for use according to claim 12, wherein said disorder is at least one of inflammatory, infectious, autoimmune, proliferative, ischemic, metabolic, neurodegenerative disorder, spinal cord injury and trauma, and acute or chronic wound or injury.

14. A therapeutically effective amount of at least one complex of nocardamine, with a metal, any combination/s of said complexes, any pharmaceutical composition/s of the complexes comprising any carrier/s, matrix or vehicle/s for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a pathological condition or a disorder in a subject in need thereof, wherein said metal is selected from the group consisting of zinc, gallium, or any ionic forms thereof.

15. The complex for use according to claim 14, wherein said metal ion is Zn^{2+}.

16. The complex for use according to claim 15, wherein said complex is a complex of nocardamine with Zn^{2+}.

17. The complex for use according to claim 14, wherein said complex is a complex of nocardamine with Ga^{3+}.

18. The complex for use according to claim 14, wherein said disorder is associated with at least one of elevated levels of pro-inflammatory cytokine/s and reduced levels of anti-inflammatory cytokine/s.

19. The complex for use according to claim 18, wherein said disorder is at least one of inflammatory, infectious, autoimmune, proliferative, ischemic, metabolic, autoimmune, neuro-degenerative disorder, spinal cord injury and trauma, and acute or chronic wound or injury.

20. The complex for use according to claim 19, wherein inflammatory disorder is at least one of inflammatory skin disorder/s, inflammatory bowel disease/s (IBD), arthritis, and inflammatory respiratory disorder/s.

21. The complex for use according to claim 20, wherein said inflammatory disorder is at least one of, at least one chronic or acute inflammatory skin disorder and at least one acute or chronic wound or injury.

22. The complex for use according to claim 29, wherein said disorder is an infectious disease caused by at least one of bacterial pathogen/s, viral pathogen/s and a parasite/s.

23. The complex for use according to claim 22, wherein said bacterial pathogen is at least one of enteropathogenic Escherichia coli (EPEC), Pseudomonas aeruginosa and Staphylococcus aureus.

24. The complex for use according to claim 22, wherein said viral pathogen is at least one of herpes, hepatitis viruses, influenza viruses, adeno-viruses, papova-viruses and pox viruses.

25. The complex for use according to claim 29, wherein said proliferative disorder is a malignancy associated with at least one of elevated level/s of pro-inflammatory cytokines and reduced level/s of anti-inflammatory cytokines.

26. The complex for use according to claim 29, wherein said metabolic disorder, is at least one of diabetes mellitus type I, diabetes mellitus type II and any diabetes related conditions.

27. A complex for use of nocardamine with zinc or any ionic forms thereof, wherein the formulation of the complex has a pH of 7.0 or 7.06.

28. The complex for use according to claim 27, wherein at least one metal ion is Zn^{2+}.

29. The complex for use according to claim 28, wherein said complex is a Nocardamine complex with Zn^{2+}.

30. A complex for use according to any one of claims 27 to 29, for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a pathological condition or a disorder in a subject in need thereof.

31. A kit comprising:

(i) at least one metal wherein at least one metal is zinc or any ionic form thereof, and

(ii) nocardamine, or a pharmaceutically acceptable derivative thereof; wherein a complex formed by said kit has a pH of 7.0 or 7.06.

32. The kit according to claim 31, for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a pathological condition or a disorder in a subject in need thereof.

33. A composition comprising at least one complex of nocardamine with zinc or any ionic form thereof, wherein the complex has a pH of 7.0 or 7.06.

34. The composition according to claim 33, wherein at least one metal ion is Zn^{2+}.

35. The composition according claim 34, wherein said complex is nocardamine with Zn^{2+}.

36. The composition according to any one of claims 33 to 35, wherein said composition is a pharmaceutical composition, said composition comprises at least one pharmaceutically acceptable carrier/s, diluent/s, excipient/s.